# US 2026/0227390 A1 · System and method for analyzing antibody co-formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0227390 A1
- Document ID: US20260227390A1
- Status: Published application
- Kind: A1
- Application number: 19/151,407
- Filed: 2024-01-29
- Published: 2026-08-06
- Earliest claimed: 2023-01-30
- Assignees: Amgen Inc.
- Applicants: Amgen Inc.
- Inventors: Aaron Daniel MILLER; Rupa PADAKI; Scott Thomas KUHNS; Jette WYPYCH
- Web page: https://patentgrep.com/patent/US20260227390A1

## CPC

- G01N 33/54313: {the carrier being characterised by its particulate form}
- C07K 16/4208: {against an idiotypic determinant on Ig}
- G01N 33/542: with steric inhibition or signal modification, e.g. fluorescent quenching
- G01N 33/563: involving antibody fragments
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/6854: {Immunoglobulins}
- G01N 33/6857: {Antibody fragments}
- G01N 33/686: {Anti-idiotype}
- C07K 16/42: against immunoglobulins
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosure provides systems and methods for detecting and quantifying two or more different antigen-binding proteins in a sample. The systems involve donor beads, acceptor beads, and conjugate proteins, which may be incubated with the sample to quantify the antigen-binding proteins via a proximity-based homogenous assay.

## Claims

### Claim 1

A system for detecting and quantifying two or more different antigen-binding proteins in a sample, which system comprises:
(a) donor beads, wherein each donor bead comprises a photosensitizer and a first binding pair member;
(b) acceptor beads, wherein each acceptor bead comprises a chemiluminescent dye and an anti-idiotype antibody that specifically binds to either of the two or more different antigen-binding proteins and;
(c) conjugate proteins, wherein each conjugate protein comprises either of the two or more different antigen-binding proteins and a second binding pair member,
wherein the first binding pair member is configured to specifically bind to the second binding pair member.

### Claim 2 (depends on 2)

The system of claim 2, wherein each of the antigen-binding proteins is an antibody, an antibody fragment, or a bispecific T cell engager (BiTE®) molecule.

### Claim 3 (depends on 1)

The system of claim 1, wherein the photosensitizer comprises phthalocyanine.

### Claim 4 (depends on 1)

The system of any claim 1, wherein the first binding pair member comprises streptavidin, glutathione S-transferase (GST), or an affinity tag peptide such as a hexahistidine or a FLAG peptide.

### Claim 5 (depends on 1)

The system of claim 1, wherein the second binding pair member comprises biotin, glutathione, or anti-affinity tag antibody such as an anti-hexahistidine antibody or an anti-FLAG antibody.

### Claim 6 (depends on 5)

The system of claim 5, wherein the first binding pair member comprises streptavidin and the second binding pair member comprises biotin.

### Claim 7 (depends on 1)

The system of claim 1, which comprises (i) a first acceptor bead conjugated to a first chemiluminescent dye and a first anti-idiotype antibody that binds to a first antigen-binding protein in the sample and (ii) a second acceptor bead conjugated to a second chemiluminescent dye and a second anti-idiotype antibody that binds to a second antigen-binding protein in the sample.

### Claim 8 (depends on 7)

The system of claim 7, wherein the first chemiluminescent dye comprises terbium (Tb) and the second chemiluminescent dye comprises europium (Eu).

### Claim 9 (depends on 7)

The system of claim 7, wherein the first antigen-binding protein is a first therapeutic antibody and the second antigen-binding protein is a second therapeutic antibody.

### Claim 10 (depends on 6)

The system of claim 6, which comprises a first conjugate protein comprising the first antigen-binding protein and biotin and a second conjugate protein comprising the second antigen-binding protein and biotin.

### Claim 11 (depends on 1)

The system of claim 1, wherein the sample is a composition comprising the two or more different antigen-binding proteins and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 1)

A method of determining a presence, absence, or concentration of two or more different antigen-binding proteins in a sample, which method comprises
(1) incubating the sample with the system of claim 1;
(2) exposing the incubated sample to light excitation; and
(3) detecting at least one chemiluminescent signal following light excitation and comparing the detected chemiluminescent signal to a predetermined reference value,
wherein the at least one detected chemiluminescent signal is inversely proportional to the concentration each of the two or more different antigen-binding proteins,
thereby determining the presence, absence, or concentration two or more different antigen-binding proteins in a sample.

### Claim 13 (depends on 12)

The method of claim 12, wherein the predetermined reference value comprises a threshold value corresponding to a concentration of each of the antigen-binding proteins, and wherein the detected chemiluminescent signal greater than the threshold value indicates that the sample lacks said antigen-binding protein or comprises said antigen-binding protein below the concentration, and a chemiluminescent signal less than or equal to the threshold value indicates that the sample comprises the antigen-binding protein at a concentration greater than or equal to the concentration.

### Claim 14 (depends on 12)

The method of claim 12, wherein the light excitation wavelength is about 500 nm to about 800 nm.

### Claim at position 15

-16. (canceled)

### Claim 17 (depends on 12)

The method of any one of claim 12, wherein each of the antigen-binding proteins is an antibody, an antibody fragment, or a bispecific T cell engager (BiTE®) molecule.

### Claim 18 (depends on 12)

The method of claim 12, wherein the system comprises (i) a first acceptor bead comprising a first chemiluminescent dye and a first anti-idiotype antibody that binds to a first antigen-binding protein in the sample and (ii) a second acceptor bead comprising a second chemiluminescent dye and a second anti-idiotype antibody that binds to a second antigen-binding protein in the sample.

### Claim 19 (depends on 18)

The method of claim 18, wherein the first antigen-binding protein comprises a first therapeutic antibody and the second antigen-binding protein comprises a second therapeutic antibody.

### Claim 20 (depends on 18)

The method of claim 18, which comprises detecting a first signal emitted from the first chemiluminescent dye and a second signal emitted from the second chemiluminescent dye.

### Claim 21 (depends on 20)

The method of claim 20, wherein the first signal and second signal comprise two different wavelengths.

### Claim 22 (depends on 21)

The method of claim 21, wherein the wavelength of the first signal is about 520 nm to about 620 nm and the wavelength of the second signal is about 520 nm to about 620 nm.

### Claim 23

(canceled)

### Claim 24 (depends on 12)

The method of claim 12, which further comprises quantifying the two or more antigen-binding proteins in the sample.

### Claim at position 24

-26. (canceled)
